Mercury Bio

Biotechnology

Overview

With a focus on advanced bio-molecular drug delivery systems, Mercury Bio is developing the therapeutic technologies to help more people heal more effectively.

Funding and backers

Total raised
$3.9M
5 rounds on record
Latest round
$2.4M
Venture round · Sep 2025 · 13 mo ago
Team
51-200
employees, estimated range
The money's age
Due for its next round
13 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 30, 2025 Raised a round Venture round $2.4M · SEC Form D Feb 13, 2025 Raised a round Venture round $2.5k · SEC Form D Mar 7, 2024 Raised a round Venture round $150k · SEC Form D Feb 3, 2023 Raised a round Venture round $1.2M · SEC Form D Oct 15, 2022 Raised a round Venture round $200k · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Venture round Sep 2025 $2.4M — SEC Form D
Venture round Feb 2025 $2.5k — SEC Form D
Venture round Mar 2024 $150k — SEC Form D
Venture round Feb 2023 $1.2M — SEC Form D
Venture round Oct 2022 $200k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Mercury Bio, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Paul LaurExecutive Officer, DirectorSEC Form D
Bruce McCormickExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Andreessen Horowitz
backs Mana.bio
High-Tech Gründerfonds
backs Draupnir Bio
NFX
backs Mana.bio
YES!Delft
backs uPATCH
Omega Funds
backs etherna
Inkef
backs Draupnir Bio
Similar startupsby what they do, their industry and backers
EYE-GO
The future of ophthalmic topical drug delivery is easy-to-use microdosing. EYE-GO is a MedTech company developing a game-changing delivery…
Mana.bio51-200 employees
Mana.bio is an AI-based drug delivery startup specializing in programmable drug delivery and gene therapy, with a focus on lipid…
Alveron PharmaSeed $5.4M · 23 mo ago · 11-50 employees
Alveron Pharma is developing a unique coagulationplatform technology with the world.
Alessa TherapeuticsVenture round $25.4M · 18 mo ago · Founded 2018 · 51-200 employees
Alessa Therapeutics is developing a proprietary drug-delivery platform for sustained and localized release of clinically proven therapies…
uPATCHSeed · 23 mo ago
We offer microneedle applicators for Drug Delivery and Biosensing.
Draupnir BioSeed $13M · 2 yr ago
Draupnir Bio is developing new innovative therapies for patients.

Financials

Total raised
$3.9M
Latest round
Venture - Series Unknown
Funding rounds
5
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $2.4M Details
Venture - Series Unknown 2025 $2.5k Details
Venture - Series Unknown 2024 $150k Details
Venture - Series Unknown 2023 $1.2M Details
Venture - Series Unknown 2022 $200k Details

People

Paul Laur
Executive Officer, Director
SEC Form D
Bruce McCormick
Executive Officer, Director
SEC Form D
Steve Kiziuk
Director
SEC Form D
Alex Koglin
Director
SEC Form D
Dana Barnard
Director
SEC Form D
Kevin McDonald
Director
SEC Form D
Mike Rice
Director
SEC Form D
John Tomes
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Santa Fe United States
HQ
Contact Mercury Bio
50-200 est. staff
3900 Paseo Del Sol, Santa Fe, NM 87507
company site